Pharmaceutical Technology

APRIL 18, 2024

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Ovarian Cancer.

Pharmaceutical 40

Pharmaceutical 40

Pharmaceutical Technology

APRIL 17, 2024

SLATE-001 is under clinical development by Gritstone Bio and currently in Phase I for Metastatic Ovarian Cancer.

40

40

Pharmaceutical Technology

NOVEMBER 14, 2022

positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. Elahere obtained the approval based on the findings on objective response rate (ORR) and duration of response (DOR) reported in the SORAYA clinical trial. positive platinum-resistant ovarian cancer.

Food and Drug Administration 98

Food and Drug Administration FDA Food Patients 98

Pharmaceutical Commerce

JANUARY 23, 2024

NK010, which showed promising anti-tumor activity and safety in preclinical studies, will be evaluated in a Phase I clinical trial for ovarian cancer.

Safety 52

Safety FDA 52

Pharmaceutical Technology

JANUARY 22, 2024

SGN-1 is under clinical development by Guangzhou Sinogen Pharmaceutical and currently in Phase II for Metastatic Ovarian Cancer.

Pharmaceutical 52

Pharmaceutical 52

Pharmaceutical Technology

DECEMBER 25, 2023

HCW-9218 is under clinical development by HCW Biologics and currently in Phase I for Ovarian Cancer.

52

52

Pharmaceutical Technology

DECEMBER 26, 2023

KSQ-4279 is under clinical development by F. Hoffmann-La Roche and currently in Phase I for Ovarian Cancer.

53

53

Pharmaceutical Technology

APRIL 14, 2023

Clinical-stage biopharmaceutical company TORL BioTherapeutics has raised $158m in a Series B financing round for advancing the development of new biologics for cancer treatment. TORL BioTherapeutics is a newly formed, US-based company focused on the development of novel antibody-based therapeutics for cancer patients.

Management 105

Management Leads Patients Healthcare 105

pharmaphorum

OCTOBER 27, 2022

Last month, pharmaphorum had the chance to speak with Dr Isabelle Ray-Coquard, professor of medical oncology (specialism sarcomas and GISTs) at the Centre Léon Bérard (CLB), a hospital 100% dedicated to cancer care and research. HRD (homologous recombination deficiency) is an important biomarker of the most advanced stages of ovarian cancer.

Patients 67

Patients Leads Specialization Networking 67

Pharmaceutical Technology

FEBRUARY 20, 2024

CX-2029 is under clinical development by CytomX Therapeutics and currently in Phase II for Ovarian Cancer.

40

40

Pharmaceutical Technology

MAY 1, 2023

Under the deal terms, Shunxi will have licence to develop, manufacture, and commercialise CTH-004 to treat several solid tumours including ovarian cancer in Greater China, including Hong Kong, Taiwan, Mainland China, and Macao. In animal models of ovarian cancer, it demonstrated promising results.

Manufacturing 52

Manufacturing Patients Leads Pharmaceutical 52

Pharmaceutical Technology

JANUARY 4, 2024

TAC-101 is under clinical development by Triumvira Immunologics and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase…

40

40

Pharmaceutical Technology

DECEMBER 21, 2023

Luveltamab tazevibulin is under clinical development by Sutro Biopharma and currently in Phase I for Epithelial Ovarian Cancer.

Biopharma 40

Biopharma 40

Pharmaceutical Technology

DECEMBER 26, 2023

Sacituzumab tirumotecan is under clinical development by Merck and currently in Phase II for Epithelial Ovarian Cancer.

40

40

Pharmaceutical Technology

JANUARY 4, 2024

SH-105 is under clinical development by Shorla Oncology and currently in Pre-Registration for Ovarian Cancer.

40

40

Pharmaceutical Technology

APRIL 4, 2023

The collaboration will see the expansion of the investigative agent’s development, including activity in models of ovarian and other cancer types. Panbela claimed that ivospemin demonstrated signs of tumour growth inhibition in clinical trials involving patients with metastatic pancreatic cancer.

Medicine 59

Medicine FDA Leads Patients 59

Pharmaceutical Technology

DECEMBER 21, 2023

SGN-1 is under clinical development by Guangzhou Sinogen Pharmaceutical and currently in Phase II for Ovarian Cancer.

Pharmaceutical 52

Pharmaceutical 52

Pharmaceutical Technology

DECEMBER 22, 2023

IDE-161 is under clinical development by Ideaya Biosciences and currently in Phase II for Metastatic Ovarian Cancer.

52

52

Pharmaceutical Technology

DECEMBER 21, 2023

Enzalutamide is under clinical development by Pfizer and currently in Phase II for Epithelial Ovarian Cancer.

40

40

Pharmacy Times

APRIL 12, 2023

Availability of clinical trials in the gynecologic cancer care space are increasing, but it is important to be mindful of current racial disparities.

Patients 49

Patients 49

Pharmaceutical Technology

DECEMBER 5, 2023

TCR-T Library is under clinical development by Alaunos Therapeutics and currently in Phase II for Ovarian Cancer.

40

40

Pharmaceutical Technology

DECEMBER 22, 2023

Dresbuxelimab is under clinical development by Akeso and currently in Phase I for Ovarian Cancer.

40

40

Pharmaceutical Technology

DECEMBER 4, 2023

XmAb-808 is under clinical development by Xencor and currently in Phase I for Epithelial Ovarian Cancer.

40

40

Pharmaceutical Technology

NOVEMBER 16, 2023

BT-7480 is under clinical development by Bicycle Therapeutics and currently in Phase II for Ovarian Cancer.

52

52

Pharmaceutical Technology

NOVEMBER 16, 2023

BT-7480 is under clinical development by Bicycle Therapeutics and currently in Phase II for Ovarian Cancer.

40

40

European Pharmaceutical Review

DECEMBER 22, 2022

Gilead-owned Kite has agreed to acquire Tmunity Therapeutics, a clinical-stage biotech focused on next-generation CAR T-therapies. Founded in 2015, Tmunity was formed by early innovators in the cell therapy field to advance early-stage academic cell therapy research and innovation into the clinic. with an option to extend further.

Manufacturing 86

Manufacturing Engineering Pharmaceutical Patients 86

Pharmaceutical Technology

NOVEMBER 3, 2023

LOAd-703 is under clinical development by Lokon Pharma and currently in Phase II for Epithelial Ovarian Cancer.

Pharma 40

Pharma 40

Pharmaceutical Technology

OCTOBER 27, 2023

BGB-10188 is under clinical development by BeiGene and currently in Phase II for Epithelial Ovarian Cancer.

40

40

Pharmaceutical Technology

JUNE 1, 2023

The US Food and Drug Administration (FDA) has granted a combination of AstraZeneca and MSD ’s Lynparza (olaparib), with standard therapies for treating BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Prostate cancer is the second-most common cancer reported in men.

Food and Drug Administration 97

Food and Drug Administration FDA Food Safety 97

Legacy MEDSearch

JANUARY 3, 2023

Burning Rock, a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, announced that its OverC Multi-Cancer Detection Blood Test (MCDBT) has been granted Breakthrough Device Designation by the US Food and Drug Administration (FDA), which is the third of its kind globally.

FDA 95

FDA Food and Drug Administration Recruitment Prospecting 95

European Pharmaceutical Review

DECEMBER 8, 2023

Cerevel’s pipeline includes multiple clinical-stage and preclinical candidates with potential across several diseases including schizophrenia, Parkinson’s disease, and mood disorders. Gonzalez, chairman and chief executive officer of AbbVie. AbbVie also agreed a $10.1

Safety 95

Safety FDA Management Pharmaceutical 95

European Pharmaceutical Review

JULY 27, 2023

ENHERTU ® (trastuzumab deruxtecan) has demonstrated clinically meaningful progression-free survival (PFS) and overall survival (OS) in topline results from the primary analysis of the ongoing DESTINY-PanTumor02 Phase II trial. These cancers include biliary tract, bladder, cervical, endometrial, ovarian and pancreatic.

Patients 86

Patients Safety Medical Medicine 86

Pharmaceutical Technology

JUNE 10, 2023

TAS-117 is under clinical development by Taiho Pharmaceutical and currently in Phase II for Chondrosarcoma. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. It was under development for the treatment of gastric cancer and multiple myeloma.

Pharmaceutical 40

Pharmaceutical Pharmaceutical products Medicine Competition 40

Pharmaceutical Technology

JUNE 10, 2023

TAS-117 is under clinical development by Taiho Pharmaceutical and currently in Phase II for Chondrosarcoma. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. It was under development for the treatment of gastric cancer and multiple myeloma.

Pharmaceutical 40

Pharmaceutical Pharmaceutical products Medicine Competition 40

Pharmacy Times

DECEMBER 16, 2022

Clinical oncology pharmacist Amy Indorf, PharmD, BCOP, discusses her presentation on the role of PARP inhibitors for ovarian cancer.

49

49

Pharmaceutical Technology

FEBRUARY 28, 2023

KFA-115 is under clinical development by Novartis and currently in Phase I for Melanoma. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Prescription 68

Prescription Pharmaceutical products Networking Manufacturing 68

Pharmaceutical Technology

JUNE 28, 2022

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended granting approval for AstraZeneca and Merck’s (MSD outside the US and Canada) Lynparza (olaparib) as adjuvant therapy for high-risk early breast cancer patients.

Safety 64

Safety Medicine Patients Medical 64